Envisagenics

335 Madison Avenue
16th Floor
New York
New York
10017
United States

About Envisagenics

Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory. The company’s mission is to boost the creation of new therapies for human diseases by reducing the complexity of biomedical big data into plausible solutions. Envisagenics focuses on the discovery of RNA therapeutics. Over 30 million people in the US suffer from genetic diseases or cancer that could be caused by mutations affecting RNA splicing. 370 human diseases are known to be caused by splicing errors, and more remain to be discovered.

YEAR FOUNDED:

2014

LEADERSHIP:

Founders: Martin Akerman and Maria Luisa Pineda

Founder and CEO: Maria Luisa Pineda

Founder and CTO: Martin Akerman

JOBS:

Please click here for Envisagenics job opportunities.

8 articles about Envisagenics

Envisagenics, Cancer Research Horizons, and Queen Mary University of London Announce Strategic Collaboration Agreement

12/13/2022

Envisagenics , an Artificial Intelligence ("AI")-driven biotechnology company that delivers therapies for RNA splicing diseases, today announced a research collaboration agreement with Cancer Research Horizons, Cancer Research UK's innovation engine, and Queen Mary University of London.
Envisagenics Announces Research Collaboration with Bristol Myers Squibb

11/29/2022

Envisagenics today announced a research collaboration agreement with Bristol Myers Squibb (NYSE: BMY).
Envisagenics is Awarded Another SBIR Grant From the National Cancer Institute to Commercialize its AI/ML Platform for Immunotherapy Development

8/2/2022

Envisagenics, Inc. announced that it was awarded a Small Business Innovation Research Direct to Phase II grant from the National Cancer Institute, part of the National Institutes of Health.
Envisagenics Raises Series A Financing to Scale Its AI-powered RNA Splicing Drug Discovery Platform

9/29/2021

Envisagenics secured Series A financing to scale its drug discovery platform and biopharmaceutical partnerships.
Envisagenics Announces Research Program with the Lung Cancer Initiative at Johnson & Johnson

4/21/2020

Envisagenics, a company developing therapeutics for RNA splicing errors that often lead to genetic disorders including cancer, announced today that it has entered into a research program agreement with the Lung Cancer Initiative (LCI) at Johnson & Johnson.
Envisagenics wins another SBIR grant from the National Cancer Institute to enhance their AI/ML platform for Immunotherapy development

10/23/2019

Envisagenics, Inc., a New York-based biotechnology company leveraging artificial intelligence (AI) and RNA-splicing analytics for discovery and development of disease specific therapeutics, announced today that it was awarded a Small Business Innovation Research (SBIR) Phase I grant from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).
Envisagenics Named North American Winner of Innovate.AI Competition, Receives $1M Investment from M12 and Madrona Venture Group

5/1/2018

Envisagenics, Inc., announced today a $1 million investment award from M12 (formerly Microsoft Ventures) and Madrona Venture Group.
Envisagenics Closes $2.35M Seed Round and Launches SpliceCore Platform

11/30/2017

The investors include 3KVC, Cosine, LLC, Dolby Family Ventures, Dynamk Capital, NY Empire State Development, and SV Angel.